Expertise in
17
conditions

Tomoki Kimura

Kochi, JP 
Expertise in
17
conditions
Kochi, JP 
OverviewLocationsClinical Research

Overview

Tomoki Kimura practices in Kochi, Japan. Mr. Kimura is highly rated in 17 conditions, according to our data. His top areas of expertise are Interstitial Lung Disease, Acute Interstitial Pneumonia, Idiopathic Pulmonary Fibrosis, Bladder Reconstruction, and Endoscopy.

His clinical research consists of co-authoring 257 peer reviewed articles and participating in 2 clinical trials. MediFind looks at clinical research from the past 15 years.

Gender
Male

Locations

Kochi, Japan
Other Locations
Seto, 4898642, Japan
Tokyo, 1138421, Japan
Nankoku, 7838505, Japan
Hirakata, 5730101, Japan
Saitama, Japan
Okazaki, Japan
Shizuoka, Japan
Hiroshima, Japan
Minami, 7348551, Japan
Neyagawa, 5728508, Japan
Nangoku, 7838505, Japan
Japan
Kyoto, 6068502, Japan
Nagoya, Japan
Nishina, Japan

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
A 52-week, Randomised, Double-blind, Double-dummy, Parallel Group, Multi-centre, Non-inferiority Study Assessing Exacerbation Rate, Additional Measures of Asthma Control and Safety in Adult and Adolescent Severe Asthmatic Participants With an Eosinophilic Phenotype Treated With GSK3511294 Compared With Mepolizumab or Benralizumab
Enrollment Status: Completed
Publish Date: October 15, 2025
Intervention Type: Biological, Drug, Device
Study Drugs: Depemokimab, Mepolizumab, Benralizumab
Study Phase: Phase 3
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
A 52-week, Randomised, Double-blind, Placebo-controlled, Parallel-group, Multi-centre Study of the Efficacy and Safety of GSK3511294 Adjunctive Therapy in Adult and Adolescent Participants With Severe Uncontrolled Asthma With an Eosinophilic Phenotype
Enrollment Status: Completed
Publish Date: November 29, 2024
Intervention Type: Biological
Study Drug: Depemokimab
Study Phase: Phase 3
View 1 Less Clinical Trial

257 Total Publications

Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579.
Correction to: Kidney Week 2025 Abstract Three-Month Interim Analysis of Ketogenic Metabolic Therapy in Japanese Patients with ADPKD SA-PO0579.
Journal: Journal of the American Society of Nephrology : JASN
Published: January 21, 2026

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Mr. Kimura's expertise for a condition
ConditionClose
View All 9 Advanced Conditions
View All 42 Experienced Conditions
Want to save this expert for later?
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile